domesticsale.info - Ciprofloxacin Extended Release Tablets - FDA prescribing information

BUY NOW For Sale 70%!
buy viagra

Cardinal er dosing of cipro

cardinal er dosing of cipro
Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Ciprofloxacin. Approved
Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Ciprofloxacin. Approved
Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Ciprofloxacin. Approved
Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Ciprofloxacin. Experimental
Acetylsalicylic acid The serum concentration of Acetylsalicylic acid can be increased when it is combined with Ciprofloxacin. Approved, Vet Approved
Afatinib The serum concentration of Afatinib can be increased when it is combined with Ciprofloxacin. Approved
Albendazole The serum concentration of Ciprofloxacin can be increased when it is combined with Albendazole. Approved, Vet Approved
Aldosterone The serum concentration of Ciprofloxacin can be decreased when it is combined with Aldosterone. Experimental
Alectinib The serum concentration of Ciprofloxacin can be increased when it is combined with Alectinib. Approved
Alfentanil The serum concentration of Ciprofloxacin can be increased when it is combined with Alfentanil. Approved, Illicit
Alfuzosin Alfuzosin may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Alitretinoin The serum concentration of Alitretinoin can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Amantadine Amantadine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Aminohippuric acid The serum concentration of Ciprofloxacin can be increased when it is combined with Aminohippuric acid. Approved
Amiodarone The serum concentration of Ciprofloxacin can be decreased when it is combined with Amiodarone. Approved, Investigational
Amitriptyline Amitriptyline may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Amlodipine The serum concentration of Ciprofloxacin can be increased when it is combined with Amlodipine. Approved
Amoxapine Amoxapine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Amprenavir The serum concentration of Ciprofloxacin can be decreased when it is combined with Amprenavir. Approved
Amsacrine The serum concentration of Ciprofloxacin can be increased when it is combined with Amsacrine. Approved
Anagrelide Ciprofloxacin may increase the QTc-prolonging activities of Anagrelide. Approved
Apixaban The serum concentration of Apixaban can be increased when it is combined with Ciprofloxacin. Approved
Apomorphine Apomorphine may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Arformoterol Arformoterol may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Arsenic trioxide The serum concentration of Arsenic trioxide can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Artemether Ciprofloxacin may increase the QTc-prolonging activities of Artemether. Approved
Asenapine Ciprofloxacin may increase the QTc-prolonging activities of Asenapine. Approved
Astemizole The serum concentration of Ciprofloxacin can be increased when it is combined with Astemizole. Approved, Withdrawn
Atazanavir Atazanavir may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Atenolol The serum concentration of Atenolol can be increased when it is combined with Ciprofloxacin. Approved
Atomoxetine Atomoxetine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Atorvastatin The risk or severity of adverse effects can be increased when Ciprofloxacin is combined with Atorvastatin. Approved
Axitinib The serum concentration of Axitinib can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Azelastine The serum concentration of Ciprofloxacin can be increased when it is combined with Azelastine. Approved
Azilsartan medoxomil Azilsartan medoxomil may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Azithromycin Azithromycin may increase the QTc-prolonging activities of Ciprofloxacin. Approved
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ciprofloxacin. Investigational
Bedaquiline Ciprofloxacin may increase the QTc-prolonging activities of Bedaquiline. Approved
Belinostat The serum concentration of Belinostat can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Benazepril Benazepril may increase the arrhythmogenic activities of Ciprofloxacin. Approved, Investigational
Benzocaine The serum concentration of Ciprofloxacin can be increased when it is combined with Benzocaine. Approved
Bepridil The serum concentration of Ciprofloxacin can be increased when it is combined with Bepridil. Approved, Withdrawn
Betamethasone The serum concentration of Betamethasone can be increased when it is combined with Ciprofloxacin. Approved, Vet Approved
Bevacizumab Bevacizumab may increase the cardiotoxic activities of Ciprofloxacin. Approved, Investigational
Biperiden The serum concentration of Ciprofloxacin can be increased when it is combined with Biperiden. Approved
Boceprevir The serum concentration of Boceprevir can be increased when it is combined with Ciprofloxacin. Withdrawn
Bortezomib Bortezomib may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Ciprofloxacin. Approved
Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Ciprofloxacin. Approved
Bromocriptine The serum concentration of Bromocriptine can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Buprenorphine The serum concentration of Ciprofloxacin can be increased when it is combined with Buprenorphine. Approved, Illicit, Investigational, Vet Approved
Buserelin Buserelin may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Buspirone The serum concentration of Ciprofloxacin can be increased when it is combined with Buspirone. Approved, Investigational
Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ciprofloxacin. Approved
Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Ciprofloxacin. Approved
Caffeine The serum concentration of Caffeine can be increased when it is combined with Ciprofloxacin. Approved
Camptothecin The serum concentration of Camptothecin can be increased when it is combined with Ciprofloxacin. Experimental
Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Ciprofloxacin. Approved
Candesartan Candesartan may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Candoxatril Candoxatril may increase the arrhythmogenic activities of Ciprofloxacin. Experimental
Captopril Captopril may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Carbamazepine The serum concentration of Carbamazepine can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Carfilzomib The serum concentration of Carfilzomib can be increased when it is combined with Ciprofloxacin. Approved
Carvedilol The serum concentration of Ciprofloxacin can be increased when it is combined with Carvedilol. Approved, Investigational
Caspofungin The serum concentration of Ciprofloxacin can be increased when it is combined with Caspofungin. Approved
Ceritinib Ciprofloxacin may increase the QTc-prolonging activities of Ceritinib. Approved
Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Ciprofloxacin. Withdrawn
Chloroquine Ciprofloxacin may increase the QTc-prolonging activities of Chloroquine. Approved, Vet Approved
Chlorpromazine Chlorpromazine may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
Chlorpropamide The serum concentration of Ciprofloxacin can be increased when it is combined with Chlorpropamide. Approved
Chlorprothixene The serum concentration of Ciprofloxacin can be increased when it is combined with Chlorprothixene. Approved, Withdrawn
Cholesterol The serum concentration of Ciprofloxacin can be increased when it is combined with Cholesterol. Experimental
Cholic Acid The serum concentration of Ciprofloxacin can be decreased when it is combined with Cholic Acid. Approved
Cilazapril Cilazapril may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Cimetidine The serum concentration of Ciprofloxacin can be decreased when it is combined with Cimetidine. Approved
Cisapride Ciprofloxacin may increase the QTc-prolonging activities of Cisapride. Approved, Investigational, Withdrawn
Cisplatin The serum concentration of Cisplatin can be increased when it is combined with Ciprofloxacin. Approved
Citalopram The serum concentration of Citalopram can be increased when it is combined with Ciprofloxacin. Approved
Clarithromycin Ciprofloxacin may increase the QTc-prolonging activities of Clarithromycin. Approved
Clobazam The serum concentration of Clobazam can be increased when it is combined with Ciprofloxacin. Approved, Illicit
Clofazimine The serum concentration of Ciprofloxacin can be increased when it is combined with Clofazimine. Approved, Investigational
Clomifene The serum concentration of Clomifene can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Clomipramine Clomipramine may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
Clonidine The serum concentration of Clonidine can be increased when it is combined with Ciprofloxacin. Approved
Clopidogrel The serum concentration of Clopidogrel can be increased when it is combined with Ciprofloxacin. Approved, Nutraceutical
Clotrimazole The serum concentration of Ciprofloxacin can be decreased when it is combined with Clotrimazole. Approved, Vet Approved
Clozapine Ciprofloxacin may increase the QTc-prolonging activities of Clozapine. Approved
Cobicistat The serum concentration of Ciprofloxacin can be increased when it is combined with Cobicistat. Approved
Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Ciprofloxacin. Approved
Colchicine The serum concentration of Colchicine can be increased when it is combined with Ciprofloxacin. Approved
Colforsin The serum concentration of Ciprofloxacin can be increased when it is combined with Colforsin. Experimental
Conjugated estrogens The serum concentration of Conjugated estrogens can be increased when it is combined with Ciprofloxacin. Approved
Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Ciprofloxacin. Approved
Crizotinib Ciprofloxacin may increase the QTc-prolonging activities of Crizotinib. Approved
Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Ciprofloxacin. Approved, Investigational
Cyclosporine The serum concentration of Ciprofloxacin can be decreased when it is combined with Cyclosporine. Approved, Investigational, Vet Approved
Cymarin Cymarin may decrease the cardiotoxic activities of Ciprofloxacin. Experimental
Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ciprofloxacin. Approved
Dabrafenib Dabrafenib may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Daclatasvir The serum concentration of Ciprofloxacin can be increased when it is combined with Daclatasvir. Approved
Dactinomycin The serum concentration of Ciprofloxacin can be increased when it is combined with Dactinomycin. Approved
Dapagliflozin The serum concentration of Dapagliflozin can be increased when it is combined with Ciprofloxacin. Approved
Dasatinib Dasatinib may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Daunorubicin The serum concentration of Ciprofloxacin can be decreased when it is combined with Daunorubicin. Approved
Debrisoquin The serum concentration of Debrisoquin can be increased when it is combined with Ciprofloxacin. Approved
Degarelix Degarelix may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Delapril Delapril may increase the arrhythmogenic activities of Ciprofloxacin. Experimental
Desflurane Desflurane may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Desipramine Desipramine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Deslanoside Deslanoside may decrease the cardiotoxic activities of Ciprofloxacin. Approved
Desloratadine The serum concentration of Ciprofloxacin can be increased when it is combined with Desloratadine. Approved, Investigational
Dexamethasone The serum concentration of Ciprofloxacin can be decreased when it is combined with Dexamethasone. Approved, Investigational, Vet Approved
Dextromethorphan The serum concentration of Ciprofloxacin can be increased when it is combined with Dextromethorphan. Approved
Diazepam The serum concentration of Diazepam can be increased when it is combined with Ciprofloxacin. Approved, Illicit, Vet Approved
Diclofenac The serum concentration of Ciprofloxacin can be increased when it is combined with Diclofenac. Approved, Vet Approved
Diethylstilbestrol The serum concentration of Diethylstilbestrol can be increased when it is combined with Ciprofloxacin. Approved
Digitoxin Digitoxin may decrease the cardiotoxic activities of Ciprofloxacin. Approved
Digoxin Digoxin may decrease the cardiotoxic activities of Ciprofloxacin. Approved
Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ciprofloxacin. Approved
Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ciprofloxacin. Experimental
Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Ciprofloxacin. Experimental
Dihydroergotamine The serum concentration of Ciprofloxacin can be increased when it is combined with Dihydroergotamine. Approved
Dihydrotestosterone The serum concentration of Dihydrotestosterone can be increased when it is combined with Ciprofloxacin. Illicit
Diltiazem The serum concentration of Ciprofloxacin can be increased when it is combined with Diltiazem. Approved
Diphenhydramine Diphenhydramine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Dipyridamole The serum concentration of Ciprofloxacin can be increased when it is combined with Dipyridamole. Approved
Disopyramide Ciprofloxacin may increase the QTc-prolonging activities of Disopyramide. Approved
Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Ciprofloxacin. Approved, Investigational
Dolasetron Ciprofloxacin may increase the QTc-prolonging activities of Dolasetron. Approved
Domperidone The serum concentration of Domperidone can be increased when it is combined with Ciprofloxacin. Approved, Investigational, Vet Approved
Doxazosin The serum concentration of Ciprofloxacin can be increased when it is combined with Doxazosin. Approved
Doxepin Doxepin may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Doxorubicin The serum concentration of Ciprofloxacin can be decreased when it is combined with Doxorubicin. Approved, Investigational
Dronabinol The serum concentration of Ciprofloxacin can be increased when it is combined with Dronabinol. Approved, Illicit
Dronedarone The serum concentration of Ciprofloxacin can be increased when it is combined with Dronedarone. Approved
Droperidol Droperidol may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Ciprofloxacin. Approved
Elbasvir The serum concentration of Elbasvir can be increased when it is combined with Ciprofloxacin. Approved
Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Eliglustat Ciprofloxacin may increase the QTc-prolonging activities of Eliglustat. Approved
Enalapril Enalapril may increase the arrhythmogenic activities of Ciprofloxacin. Approved, Vet Approved
Enalaprilat Enalaprilat may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Enasidenib The serum concentration of Enasidenib can be increased when it is combined with Ciprofloxacin. Approved
Enzalutamide The serum concentration of Ciprofloxacin can be increased when it is combined with Enzalutamide. Approved
Epinastine The serum concentration of Epinastine can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Eprosartan Eprosartan may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Ergonovine The serum concentration of Ciprofloxacin can be increased when it is combined with Ergonovine. Approved
Ergotamine The serum concentration of Ciprofloxacin can be increased when it is combined with Ergotamine. Approved
Eribulin Eribulin may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Erythromycin Erythromycin may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
Escitalopram Ciprofloxacin may increase the QTc-prolonging activities of Escitalopram. Approved, Investigational
Estradiol The serum concentration of Estradiol can be increased when it is combined with Ciprofloxacin. Approved, Investigational, Vet Approved
Estramustine The serum concentration of Ciprofloxacin can be increased when it is combined with Estramustine. Approved
Estriol The serum concentration of Ciprofloxacin can be decreased when it is combined with Estriol. Approved, Vet Approved
Estrone The serum concentration of Ciprofloxacin can be decreased when it is combined with Estrone. Approved
Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be increased when it is combined with Ciprofloxacin. Approved
Etoposide The serum concentration of Ciprofloxacin can be increased when it is combined with Etoposide. Approved
Etravirine The serum concentration of Ciprofloxacin can be increased when it is combined with Etravirine. Approved
Everolimus The serum concentration of Everolimus can be increased when it is combined with Ciprofloxacin. Approved
Ezetimibe The serum concentration of Ezetimibe can be increased when it is combined with Ciprofloxacin. Approved
Ezogabine Ezogabine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Famotidine Famotidine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Felbamate Felbamate may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Felodipine The serum concentration of Ciprofloxacin can be increased when it is combined with Felodipine. Approved, Investigational
Fentanyl The serum concentration of Ciprofloxacin can be increased when it is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved
Fesoterodine The serum concentration of Fesoterodine can be increased when it is combined with Ciprofloxacin. Approved
Fexofenadine The serum concentration of Fexofenadine can be increased when it is combined with Ciprofloxacin. Approved
Fidaxomicin The serum concentration of Fidaxomicin can be increased when it is combined with Ciprofloxacin. Approved
Fimasartan Fimasartan may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Fingolimod Fingolimod may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Flecainide Ciprofloxacin may increase the QTc-prolonging activities of Flecainide. Approved, Withdrawn
Fluconazole Fluconazole may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Fluoxetine The serum concentration of Ciprofloxacin can be increased when it is combined with Fluoxetine. Approved, Vet Approved
Flupentixol The serum concentration of Ciprofloxacin can be increased when it is combined with Flupentixol. Approved, Withdrawn
Fluphenazine The serum concentration of Ciprofloxacin can be increased when it is combined with Fluphenazine. Approved
Flurazepam The serum concentration of Ciprofloxacin can be increased when it is combined with Flurazepam. Approved, Illicit
Fluticasone furoate The serum concentration of Fluticasone furoate can be increased when it is combined with Ciprofloxacin. Approved
Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Ciprofloxacin. Approved
Fluvoxamine The serum concentration of Ciprofloxacin can be increased when it is combined with Fluvoxamine. Approved, Investigational
Forasartan Forasartan may increase the arrhythmogenic activities of Ciprofloxacin. Experimental
Formoterol Formoterol may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Foscarnet Foscarnet may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Fosinopril Fosinopril may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Fosphenytoin Fosphenytoin may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Gadobenic acid Ciprofloxacin may increase the QTc-prolonging activities of Gadobenic acid. Approved
Galantamine Galantamine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Gefitinib The serum concentration of Gefitinib can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Ciprofloxacin. Approved
Gemifloxacin Ciprofloxacin may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational
Genistein The serum concentration of Ciprofloxacin can be increased when it is combined with Genistein. Investigational
Gitoformate Gitoformate may decrease the cardiotoxic activities of Ciprofloxacin. Experimental
Glecaprevir The serum concentration of Glecaprevir can be increased when it is combined with Ciprofloxacin. Approved
Glyburide The serum concentration of Ciprofloxacin can be increased when it is combined with Glyburide. Approved
Glycerin The serum concentration of Ciprofloxacin can be increased when it is combined with Glycerin. Approved, Investigational
Goserelin Goserelin may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Gramicidin D The serum concentration of Ciprofloxacin can be increased when it is combined with Gramicidin D. Approved
Granisetron Ciprofloxacin may increase the QTc-prolonging activities of Granisetron. Approved, Investigational
Grazoprevir The serum concentration of Grazoprevir can be increased when it is combined with Ciprofloxacin. Approved
Grepafloxacin The serum concentration of Grepafloxacin can be increased when it is combined with Ciprofloxacin. Withdrawn
Haloperidol Haloperidol may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Histrelin Histrelin may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Hydrocortisone The serum concentration of Hydrocortisone can be increased when it is combined with Ciprofloxacin. Approved, Vet Approved
Hydroxyzine Hydroxyzine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Ibandronate Ibandronate may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Ibuprofen The serum concentration of Ibuprofen can be increased when it is combined with Ciprofloxacin. Approved
Ibutilide Ciprofloxacin may increase the QTc-prolonging activities of Ibutilide. Approved
Idelalisib The serum concentration of Idelalisib can be increased when it is combined with Ciprofloxacin. Approved
Iloperidone Ciprofloxacin may increase the QTc-prolonging activities of Iloperidone. Approved
Imatinib The serum concentration of Imatinib can be increased when it is combined with Ciprofloxacin. Approved
Imidapril Imidapril may increase the arrhythmogenic activities of Ciprofloxacin. Investigational
Imipramine Imipramine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Indacaterol Indacaterol may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Indapamide Indapamide may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Indinavir The serum concentration of Ciprofloxacin can be decreased when it is combined with Indinavir. Approved
Indomethacin The serum concentration of Ciprofloxacin can be increased when it is combined with Indomethacin. Approved, Investigational
Inotuzumab ozogamicin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ciprofloxacin. Approved
Irbesartan Irbesartan may increase the arrhythmogenic activities of Ciprofloxacin. Approved, Investigational
Irinotecan The serum concentration of Irinotecan can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Isavuconazonium The serum concentration of Ciprofloxacin can be increased when it is combined with Isavuconazonium. Approved, Investigational
Isoflurane Isoflurane may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
Isradipine Isradipine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Itraconazole Itraconazole may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Ivabradine Ivabradine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Ivacaftor The serum concentration of Ciprofloxacin can be increased when it is combined with Ivacaftor. Approved
Ivermectin The serum concentration of Ivermectin can be increased when it is combined with Ciprofloxacin. Approved, Vet Approved
Ketamine The serum concentration of Ciprofloxacin can be increased when it is combined with Ketamine. Approved, Vet Approved
Ketazolam The serum concentration of Ketazolam can be increased when it is combined with Ciprofloxacin. Approved
Ketoconazole Ketoconazole may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Lamotrigine The serum concentration of Lamotrigine can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Ciprofloxacin. Experimental
Lansoprazole The serum concentration of Lansoprazole can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Lapatinib Lapatinib may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Ciprofloxacin. Approved
Lenalidomide The serum concentration of Lenalidomide can be increased when it is combined with Ciprofloxacin. Approved
Lenvatinib Ciprofloxacin may increase the QTc-prolonging activities of Lenvatinib. Approved
Leuprolide Leuprolide may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Levetiracetam The serum concentration of Levetiracetam can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Levofloxacin Ciprofloxacin may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational
Levomilnacipran The serum concentration of Levomilnacipran can be increased when it is combined with Ciprofloxacin. Approved
Lidocaine The serum concentration of Ciprofloxacin can be increased when it is combined with Lidocaine. Approved, Vet Approved
Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Ciprofloxacin. Approved
Lisinopril Lisinopril may increase the arrhythmogenic activities of Ciprofloxacin. Approved, Investigational
Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Ciprofloxacin. Approved
Lithium Lithium may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Lomitapide The serum concentration of Ciprofloxacin can be increased when it is combined with Lomitapide. Approved
Loperamide The serum concentration of Loperamide can be increased when it is combined with Ciprofloxacin. Approved
Lopinavir The serum concentration of Ciprofloxacin can be increased when it is combined with Lopinavir. Approved
Loratadine The serum concentration of Ciprofloxacin can be increased when it is combined with Loratadine. Approved
Losartan Losartan may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Lovastatin The serum concentration of Ciprofloxacin can be increased when it is combined with Lovastatin. Approved, Investigational
Lumacaftor The serum concentration of Ciprofloxacin can be decreased when it is combined with Lumacaftor. Approved
Lumefantrine Ciprofloxacin may increase the QTc-prolonging activities of Lumefantrine. Approved
Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ciprofloxacin. Illicit, Withdrawn
Mannitol The serum concentration of Mannitol can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Maprotiline Maprotiline may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Mebendazole The serum concentration of Ciprofloxacin can be increased when it is combined with Mebendazole. Approved, Vet Approved
Mefloquine Mefloquine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Megestrol acetate The serum concentration of Ciprofloxacin can be increased when it is combined with Megestrol acetate. Approved, Vet Approved
Meprobamate The serum concentration of Ciprofloxacin can be increased when it is combined with Meprobamate. Approved, Illicit
Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Ciprofloxacin. Experimental
Methadone Methadone may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Ciprofloxacin. Approved
Methotrimeprazine Methotrimeprazine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ciprofloxacin. Approved
Methylprednisolone The serum concentration of Methylprednisolone can be increased when it is combined with Ciprofloxacin. Approved, Vet Approved
Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Ciprofloxacin. Approved
Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Ciprofloxacin. Experimental
Metoclopramide Metoclopramide may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Metronidazole Metronidazole may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Ciprofloxacin. Experimental
Mibefradil The serum concentration of Ciprofloxacin can be increased when it is combined with Mibefradil. Withdrawn
Miconazole The serum concentration of Ciprofloxacin can be increased when it is combined with Miconazole. Approved, Investigational, Vet Approved
Midazolam The serum concentration of Ciprofloxacin can be decreased when it is combined with Midazolam. Approved, Illicit
Mifepristone Mifepristone may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Mirabegron Mirabegron may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Mirtazapine Mirtazapine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Mitomycin The serum concentration of Ciprofloxacin can be increased when it is combined with Mitomycin. Approved
Mitoxantrone The serum concentration of Ciprofloxacin can be decreased when it is combined with Mitoxantrone. Approved, Investigational
Moexipril Moexipril may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Morphine The serum concentration of Morphine can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Moxifloxacin Moxifloxacin may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Nadolol The serum concentration of Nadolol can be increased when it is combined with Ciprofloxacin. Approved
Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Ciprofloxacin. Approved
Naloxone The serum concentration of Naloxone can be increased when it is combined with Ciprofloxacin. Approved, Vet Approved
Naltrexone The serum concentration of Ciprofloxacin can be increased when it is combined with Naltrexone. Approved, Investigational, Vet Approved
Naringenin The serum concentration of Ciprofloxacin can be increased when it is combined with Naringenin. Experimental
Nefazodone The serum concentration of Ciprofloxacin can be decreased when it is combined with Nefazodone. Approved, Withdrawn
Nelfinavir Nelfinavir may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Neostigmine The serum concentration of Ciprofloxacin can be increased when it is combined with Neostigmine. Approved, Vet Approved
Nicardipine Nicardipine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Ciprofloxacin. Approved
Nifedipine The serum concentration of Ciprofloxacin can be decreased when it is combined with Nifedipine. Approved
Nilotinib The serum concentration of Nilotinib can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Ciprofloxacin. Approved
Nisoldipine The serum concentration of Ciprofloxacin can be increased when it is combined with Nisoldipine. Approved
Nitrazepam The serum concentration of Ciprofloxacin can be increased when it is combined with Nitrazepam. Approved
Nitrendipine The serum concentration of Ciprofloxacin can be increased when it is combined with Nitrendipine. Approved
Nizatidine The serum concentration of Nizatidine can be increased when it is combined with Ciprofloxacin. Approved
Norethisterone The serum concentration of Ciprofloxacin can be decreased when it is combined with Norethisterone. Approved
Norfloxacin Norfloxacin may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Nortriptyline Nortriptyline may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Octreotide Octreotide may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Odanacatib The serum concentration of Odanacatib can be increased when it is combined with Ciprofloxacin. Investigational
Ofloxacin Ciprofloxacin may increase the QTc-prolonging activities of Ofloxacin. Approved
Olanzapine Olanzapine may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Oleandrin Oleandrin may decrease the cardiotoxic activities of Ciprofloxacin. Experimental
Olmesartan Olmesartan may increase the arrhythmogenic activities of Ciprofloxacin. Approved, Investigational
Olodaterol Olodaterol may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Omapatrilat Omapatrilat may increase the arrhythmogenic activities of Ciprofloxacin. Investigational
Ombitasvir The serum concentration of Ombitasvir can be increased when it is combined with Ciprofloxacin. Approved
Omeprazole The serum concentration of Ciprofloxacin can be increased when it is combined with Omeprazole. Approved, Investigational, Vet Approved
Ondansetron Ciprofloxacin may increase the QTc-prolonging activities of Ondansetron. Approved
Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Ciprofloxacin. Approved
Ouabain Ouabain may decrease the cardiotoxic activities of Ciprofloxacin. Approved
Oxytocin Oxytocin may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
P-Nitrophenol The serum concentration of Ciprofloxacin can be increased when it is combined with P-Nitrophenol. Experimental
Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ciprofloxacin. Approved, Vet Approved
Paliperidone Ciprofloxacin may increase the QTc-prolonging activities of Paliperidone. Approved
Palmitic Acid The serum concentration of Ciprofloxacin can be increased when it is combined with Palmitic Acid. Experimental
Panobinostat Ciprofloxacin may increase the QTc-prolonging activities of Panobinostat. Approved, Investigational
Pantoprazole The serum concentration of Ciprofloxacin can be increased when it is combined with Pantoprazole. Approved
Paroxetine Paroxetine may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Pasireotide Pasireotide may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Ciprofloxacin. Approved
Pentamidine Ciprofloxacin may increase the QTc-prolonging activities of Pentamidine. Approved
Perflutren Ciprofloxacin may increase the QTc-prolonging activities of Perflutren. Approved
Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Ciprofloxacin. Approved, Vet Approved, Withdrawn
Perindopril Perindopril may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Peruvoside Peruvoside may decrease the cardiotoxic activities of Ciprofloxacin. Experimental
Phenobarbital The serum concentration of Ciprofloxacin can be decreased when it is combined with Phenobarbital. Approved
Phenytoin The therapeutic efficacy of Phenytoin can be decreased when used in combination with Ciprofloxacin. Approved, Vet Approved
Pibrentasvir The serum concentration of Pibrentasvir can be increased when it is combined with Ciprofloxacin. Approved
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ciprofloxacin. Approved
Pimozide The serum concentration of Ciprofloxacin can be increased when it is combined with Pimozide. Approved
Pirfenidone The serum concentration of Pirfenidone can be increased when it is combined with Ciprofloxacin. Investigational
Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Ciprofloxacin. Approved
Platelet Activating Factor The serum concentration of Ciprofloxacin can be decreased when it is combined with Platelet Activating Factor. Experimental
Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Ciprofloxacin. Approved
Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Ciprofloxacin. Approved
Posaconazole Posaconazole may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational, Vet Approved
Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Ciprofloxacin. Approved
Prazosin The serum concentration of Ciprofloxacin can be increased when it is combined with Prazosin. Approved
Prednisolone The serum concentration of Prednisolone can be increased when it is combined with Ciprofloxacin. Approved, Vet Approved
Prednisone The serum concentration of Prednisone can be increased when it is combined with Ciprofloxacin. Approved, Vet Approved
Primaquine Ciprofloxacin may increase the QTc-prolonging activities of Primaquine. Approved
Probenecid The serum concentration of Ciprofloxacin can be increased when it is combined with Probenecid. Approved
Procainamide Ciprofloxacin may increase the QTc-prolonging activities of Procainamide. Approved
Progesterone The serum concentration of Ciprofloxacin can be decreased when it is combined with Progesterone. Approved, Vet Approved
Promazine Promazine may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
Promethazine Promethazine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Propafenone Ciprofloxacin may increase the QTc-prolonging activities of Propafenone. Approved
Propofol Propofol may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational, Vet Approved
Propranolol The serum concentration of Propranolol can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Ciprofloxacin. Experimental
Protriptyline Protriptyline may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Ciprofloxacin. Approved
Quercetin The serum concentration of Ciprofloxacin can be increased when it is combined with Quercetin. Experimental
Quetiapine The serum concentration of Quetiapine can be increased when it is combined with Ciprofloxacin. Approved
Quinacrine The serum concentration of Ciprofloxacin can be increased when it is combined with Quinacrine. Approved
Quinapril Quinapril may increase the arrhythmogenic activities of Ciprofloxacin. Approved, Investigational
Quinidine The serum concentration of Ciprofloxacin can be increased when it is combined with Quinidine. Approved
Quinine The serum concentration of Ciprofloxacin can be increased when it is combined with Quinine. Approved
Ramipril Ramipril may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Ranitidine The serum concentration of Ciprofloxacin can be increased when it is combined with Ranitidine. Approved
Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Reboxetine The serum concentration of Ciprofloxacin can be increased when it is combined with Reboxetine. Approved, Investigational
Regorafenib The serum concentration of Ciprofloxacin can be increased when it is combined with Regorafenib. Approved
Rescinnamine Rescinnamine may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Reserpine The serum concentration of Ciprofloxacin can be decreased when it is combined with Reserpine. Approved
Rifampicin The serum concentration of Ciprofloxacin can be decreased when it is combined with Rifampicin. Approved
Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Rilpivirine Rilpivirine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Risperidone Risperidone may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Ritonavir Ritonavir may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Ciprofloxacin. Approved
Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Ciprofloxacin. Approved
Rolapitant The serum concentration of Ciprofloxacin can be increased when it is combined with Rolapitant. Approved
Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Ropinirole The serum concentration of Ropinirole can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Ropivacaine The serum concentration of Ropivacaine can be increased when it is combined with Ciprofloxacin. Approved
Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Ciprofloxacin. Approved
Sacubitril Sacubitril may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Salbutamol Salbutamol may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
Salicylic acid The serum concentration of Salicylic acid can be increased when it is combined with Ciprofloxacin. Approved, Vet Approved
Salmeterol Salmeterol may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Saprisartan Saprisartan may increase the arrhythmogenic activities of Ciprofloxacin. Experimental
Saquinavir Ciprofloxacin may increase the QTc-prolonging activities of Saquinavir. Approved, Investigational
Saralasin Saralasin may increase the arrhythmogenic activities of Ciprofloxacin. Investigational
Scopolamine The serum concentration of Ciprofloxacin can be increased when it is combined with Scopolamine. Approved
Selegiline The serum concentration of Ciprofloxacin can be increased when it is combined with Selegiline. Approved, Investigational, Vet Approved
Selexipag The serum concentration of Selexipag can be increased when it is combined with Ciprofloxacin. Approved
Sertraline Sertraline may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Sevoflurane Sevoflurane may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
Silodosin The serum concentration of Silodosin can be increased when it is combined with Ciprofloxacin. Approved
Simeprevir The serum concentration of Simeprevir can be increased when it is combined with Ciprofloxacin. Approved
Simvastatin The serum concentration of Ciprofloxacin can be increased when it is combined with Simvastatin. Approved
Sirolimus The serum concentration of Ciprofloxacin can be decreased when it is combined with Sirolimus. Approved, Investigational
Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Ciprofloxacin. Approved
Solifenacin Solifenacin may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Sorafenib Sorafenib may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Sotalol Ciprofloxacin may increase the QTc-prolonging activities of Sotalol. Approved
Sparfloxacin The serum concentration of Sparfloxacin can be increased when it is combined with Ciprofloxacin. Approved
Sphingosine The serum concentration of Sphingosine can be increased when it is combined with Ciprofloxacin. Experimental
Spirapril Spirapril may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Spironolactone Spironolactone may increase the arrhythmogenic activities of Ciprofloxacin. Approved
St. John's Wort The serum concentration of Ciprofloxacin can be decreased when it is combined with St. John's Wort. Nutraceutical
Staurosporine The serum concentration of Ciprofloxacin can be increased when it is combined with Staurosporine. Experimental
Streptozocin The serum concentration of Ciprofloxacin can be decreased when it is combined with Streptozocin. Approved
Sulfamethoxazole Sulfamethoxazole may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Sulfinpyrazone The serum concentration of Ciprofloxacin can be increased when it is combined with Sulfinpyrazone. Approved
Sulfisoxazole Sulfisoxazole may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
Sumatriptan The serum concentration of Ciprofloxacin can be increased when it is combined with Sumatriptan. Approved, Investigational
Sunitinib Sunitinib may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Tacrine The serum concentration of Ciprofloxacin can be increased when it is combined with Tacrine. Withdrawn
Tacrolimus The serum concentration of Ciprofloxacin can be decreased when it is combined with Tacrolimus. Approved, Investigational
Tamoxifen Tamoxifen may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Tasosartan Tasosartan may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Taurocholic Acid The serum concentration of Taurocholic Acid can be increased when it is combined with Ciprofloxacin. Experimental
Technetium Tc-99m sestamibi The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ciprofloxacin. Approved
Telaprevir The serum concentration of Telaprevir can be increased when it is combined with Ciprofloxacin. Withdrawn
Telavancin Ciprofloxacin may increase the QTc-prolonging activities of Telavancin. Approved
Telithromycin Ciprofloxacin may increase the QTc-prolonging activities of Telithromycin. Approved
Telmisartan Telmisartan may increase the arrhythmogenic activities of Ciprofloxacin. Approved, Investigational
Temocapril Temocapril may increase the arrhythmogenic activities of Ciprofloxacin. Experimental, Investigational
Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Ciprofloxacin. Approved
Terazosin The serum concentration of Ciprofloxacin can be increased when it is combined with Terazosin. Approved
Terbutaline Terbutaline may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Terfenadine The serum concentration of Ciprofloxacin can be increased when it is combined with Terfenadine. Withdrawn
Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Ciprofloxacin. Experimental
Tesmilifene The serum concentration of Ciprofloxacin can be decreased when it is combined with Tesmilifene. Investigational
Testosterone The serum concentration of Ciprofloxacin can be increased when it is combined with Testosterone. Approved, Investigational
Tetrabenazine Ciprofloxacin may increase the QTc-prolonging activities of Tetrabenazine. Approved
Thioridazine Ciprofloxacin may increase the QTc-prolonging activities of Thioridazine. Withdrawn
Thiothixene Thiothixene may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Thyroid, porcine The serum concentration of Thyroid, porcine can be decreased when it is combined with Ciprofloxacin. Approved
Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Ciprofloxacin. Approved
Timolol The serum concentration of Timolol can be increased when it is combined with Ciprofloxacin. Approved
Tizanidine Tizanidine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Tolterodine Tolterodine may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Ciprofloxacin. Approved
Topotecan The serum concentration of Topotecan can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Toremifene The serum concentration of Toremifene can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Trandolapril Trandolapril may increase the arrhythmogenic activities of Ciprofloxacin. Approved
Trastuzumab Trastuzumab may increase the cardiotoxic activities of Ciprofloxacin. Approved, Investigational
Trastuzumab emtansine The serum concentration of Trastuzumab emtansine can be increased when it is combined with Ciprofloxacin. Approved
Trazodone Trazodone may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Treprostinil Treprostinil may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Trifluoperazine The serum concentration of Ciprofloxacin can be increased when it is combined with Trifluoperazine. Approved
Triflupromazine The serum concentration of Ciprofloxacin can be increased when it is combined with Triflupromazine. Approved, Vet Approved
Trimethoprim Trimethoprim may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
Trimipramine Trimipramine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Triptorelin Triptorelin may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Vet Approved
Troleandomycin The serum concentration of Ciprofloxacin can be increased when it is combined with Troleandomycin. Approved
Ubidecarenone The serum concentration of Ubidecarenone can be increased when it is combined with Ciprofloxacin. Experimental
Ulipristal The serum concentration of Ulipristal can be increased when it is combined with Ciprofloxacin. Approved
Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Ciprofloxacin. Approved
Valsartan Valsartan may increase the arrhythmogenic activities of Ciprofloxacin. Approved, Investigational
Vandetanib Ciprofloxacin may increase the QTc-prolonging activities of Vandetanib. Approved
Vardenafil Vardenafil may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Vecuronium The serum concentration of Vecuronium can be increased when it is combined with Ciprofloxacin. Approved
Velpatasvir The serum concentration of Velpatasvir can be increased when it is combined with Ciprofloxacin. Approved
Vemurafenib Ciprofloxacin may increase the QTc-prolonging activities of Vemurafenib. Approved
Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Ciprofloxacin. Approved
Venlafaxine Venlafaxine may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Verapamil The serum concentration of Ciprofloxacin can be decreased when it is combined with Verapamil. Approved
Vilanterol Vilanterol may increase the QTc-prolonging activities of Ciprofloxacin. Approved
Vinblastine The serum concentration of Ciprofloxacin can be decreased when it is combined with Vinblastine. Approved
Vincristine The serum concentration of Vincristine can be increased when it is combined with Ciprofloxacin. Approved, Investigational
Vincristine The serum concentration of Ciprofloxacin can be decreased when it is combined with Vincristine. Approved, Investigational
Vinorelbine The serum concentration of Ciprofloxacin can be increased when it is combined with Vinorelbine. Approved, Investigational
Vismodegib The serum concentration of Vismodegib can be increased when it is combined with Ciprofloxacin. Approved
Voriconazole Voriconazole may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Vorinostat Vorinostat may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational
Voxilaprevir The serum concentration of Voxilaprevir can be increased when it is combined with Ciprofloxacin. Approved
Zidovudine The serum concentration of Zidovudine can be increased when it is combined with Ciprofloxacin. Approved
Zimelidine The serum concentration of Ciprofloxacin can be increased when it is combined with Zimelidine. Withdrawn
Ziprasidone Ciprofloxacin may increase the QTc-prolonging activities of Ziprasidone. Approved
Zofenopril Zofenopril may increase the arrhythmogenic activities of Ciprofloxacin. Experimental
Zuclopenthixol Ciprofloxacin may increase the QTc-prolonging activities of Zuclopenthixol. Approved, Investigational

Source: https://www.drugbank.ca/drugs/DB00537


BUY NOW For Sale 70%!
buy viagra

Weapons of Mass Casualties and Terrorism Response Handbook Male uti treatment cipro

Cardinal er dosing of cipro How much cipro for uti - St Elizabeth Hospice Education
Cardinal er dosing of cipro Requip xl extended-release tablets - GSK Source
Cardinal er dosing of cipro Ciprofloxacin - DrugBank
Cardinal er dosing of cipro 3 Ways to Treat Bladder Stones in Cats - wikiHow
Cardinal er dosing of cipro AFSPA - News
Cardinal er dosing of cipro Anwendung und Dosierung von Kurkuma
Cardinal er dosing of cipro Cached
Can I Eat Dairy on Amoxicillin? M Cipro - Side Effects, Interactions Dosages Cipro is no better than a PLACEBO at treating chronic prostatitis Ciprofloxacin nursing considerations - MedHelp Drugs@FDA: FDA Approved Drug Products Eudemons Online - Free to Play - Pet PvP Fantasy MMORPG
BUY NOW For Sale 70%!
buy viagra